Cellular Logistics and Allele Biotech, a company that explores the mechanisms of biological processes to develop technologies and products for biomedical researchers, have partnered, the company announced recently.

The two companies look to develop regenerative medicine products to treat ischemic heart disease.

According to a release, the relationship was bolstered by the Catalyze Award that Cellular Logistics received, which will accelerate the development studies toward clinical-grade manufacturing of the company’s lead product, SolusTM.

“Translating SolusTM toward clinical-grade production is an exciting and transformative step forward,” Cellular Logistics Board Chair Amish Raval M.D. said in a statement. “Our patients with advanced heart disease such as refractory angina and heart failure following myocardial infarction are desperate for new treatments that can save their life and improve their quality of life.”

The manufacturing of SolusTM will take place at Allele’s stem cell-dedicated cGMP facility in San Diego.